Free Trial

Elekta AB (publ) (OTCMKTS:EKTAY) Stock Price Passes Below 50-Day Moving Average - Should You Sell?

Elekta AB (publ) logo with Medical background

Shares of Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $6.60 and traded as low as $5.93. Elekta AB (publ) shares last traded at $5.96, with a volume of 11,730 shares trading hands.

Elekta AB (publ) Trading Down 2.4 %

The company has a quick ratio of 0.74, a current ratio of 0.99 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $2.28 billion, a PE ratio of 21.27 and a beta of 1.21. The stock's fifty day moving average price is $6.58 and its two-hundred day moving average price is $6.69.

Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) last released its earnings results on Wednesday, August 28th. The company reported $0.04 EPS for the quarter. The firm had revenue of $359.76 million during the quarter. Elekta AB (publ) had a return on equity of 12.23% and a net margin of 6.25%. Sell-side analysts anticipate that Elekta AB will post 0.41 earnings per share for the current year.

Elekta AB (publ) Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, September 27th. Stockholders of record on Monday, September 9th were issued a $0.114 dividend. The ex-dividend date of this dividend was Monday, September 9th. Elekta AB (publ)'s payout ratio is currently 42.86%.

Elekta AB (publ) Company Profile

(Get Free Report)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.

See Also

Should you invest $1,000 in Elekta AB (publ) right now?

Before you consider Elekta AB (publ), you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elekta AB (publ) wasn't on the list.

While Elekta AB (publ) currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Whitestone REIT is Outperforming in 2024: 35% Growth & Monthly Dividends
Why SoundHound Stock Dip Could Mean Big Gains for 2025 Investors
Nintendo Stock: Buy Before the 2025 Switch Platform Hits!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines